Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microenvironment at a Distance: Multi-Endocrine-Organ Radiomics to Identify Systemic Signatures in PSMA-Negative Prostate Cancer.

Cancers·2026
Same author

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same author

The predictive role of [<sup>177</sup>Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis.

European journal of nuclear medicine and molecular imaging·2026
Same author

Fluorescence properties of methylene blue conjugated to normal/cancerous human tissues for spectral discrimination of breast cancer stages (I-IV).

Biomedical optics express·2026
Same author

The ISG Atlas: a loss-of-function analysis characterizes antiviral properties of interferon stimulated genes.

Nature communications·2026
Same author

3D-ring CZT gamma cameras in theranostics: is it a revolution?

EJNMMI reports·2026
Same journal

Discordant <sup>18</sup>F-FES PET and ER immunohistochemistry in ER-positive bone metastasis: a potential imaging pitfall.

European journal of nuclear medicine and molecular imaging·2026
Same journal

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.

European journal of nuclear medicine and molecular imaging·2026
Same journal

[<sup>18</sup>F]RO948 Tau PET in early and late onset Alzheimer's disease: associations with plasma p-tau 217, atrophy and cognition.

European journal of nuclear medicine and molecular imaging·2026
Same journal

Metformin and renal dosimetry in patients undergoing [<sup>177</sup>Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry.

European journal of nuclear medicine and molecular imaging·2026
Same journal

Comparison of [<sup>18</sup>F]DCFPyL and [<sup>18</sup>F]FAPI-74 PET/CT imaging in metastatic prostate cancer.

European journal of nuclear medicine and molecular imaging·2026
Same journal

Genotype-dependent [<sup>18</sup>F]FDOPA uptake: quantitative evidence from a genetically stratified PPGL cohort.

European journal of nuclear medicine and molecular imaging·2026
See all related articles
  1. Home
  3. Is There A Role For Early Sstr-targeting Prrt In Gep-net?
  1. Home
  3. Is There A Role For Early Sstr-targeting Prrt In Gep-net?

Related Experiment Video

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Is there a role for early SSTR-targeting PRRT in GEP-NET?

Giorgia Ricciardello1, Greta Celesti1, Matteo Bauckneht2,3

  • 1Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine, Messina University, Messina, Italy.

European Journal of Nuclear Medicine and Molecular Imaging
|June 3, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Peptide receptor radionuclide therapy (PRRT) shows promise in earlier treatment for neuroendocrine tumors. PRRT may improve surgical outcomes and survival when used before surgery or as a first-line option.

Keywords:
Gastroenteropancreatic neuroendocrine tumorLutetium-177Peptide-receptorRLTRadioligand therapyRadionuclide therapyTheranostics

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Experiment Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Area of Science:

  • Oncology
  • Nuclear Medicine

Background:

  • Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues like [¹⁷⁷Lu]Lu-DOTATATE is approved for progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) as second-line treatment.
  • Emerging evidence suggests PRRT may have a role in earlier treatment settings for GEP-NETs.

Purpose of the Study:

  • To systematically review the literature on neoadjuvant, adjuvant, or first-line PRRT in GEP-NETs.
  • To evaluate the clinical utility and outcomes of PRRT in earlier treatment settings.

Main Methods:

  • A systematic review adhering to PRISMA guidelines was performed.
  • Searches of PubMed and clinicaltrials.gov identified 25 eligible studies (case reports, original papers, clinical trial protocols).
  • Data extracted included clinical setting, patient characteristics, treatment, and oncologic/surgical outcomes.

Main Results:

  • Neoadjuvant PRRT demonstrated tumor shrinkage and conversion to resectable disease in up to 45% of patients, with objective response rates up to 70%.
  • PRRT before surgery showed improved feasibility, promising survival benefits, and high response rates.
  • The NETTER-2 trial supports first-line [¹⁷⁷Lu]Lu-DOTATATE for SSTR-positive G2-G3 GEP-NETs, improving progression-free survival; evidence for adjuvant use is lacking.

Conclusions:

  • PRRT may be a valuable option in neoadjuvant and first-line settings for selected GEP-NET patients, enhancing resectability and survival.
  • Further prospective, randomized studies are essential to establish optimal selection criteria, timing, and long-term impact.